Boston Scientific Corporation (BSX) has delivered strong performance with Q2 2025 earnings surpassing estimates, leading to a boost in their annual profit forecast. The company's stock value, as a result, has surged, pleasing investors with a solid 173% return over the past five years. The robust Q2 performance was followed by an upward adjustment in full-year guidance. The optimism displayed by Boston Scientific has encouraged many industry analysts to raise their price targets. The
Raymond James, Baird, Oppenheimer, UBS, RBC Capital and Truist have all increased their price targets for BSX stock. Furthermore, the company's
FARAPULSE received FDA approval for expanded labeling, enhancing their standing in the medical device market. Looking ahead, the company projects
sales growth of up to 17% this year, and insiders have sold US$2.3M in stock, indicating potential weakness.
Boston Scientific Corp BSX News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Sat, 26 Jul 2025 23:12:52 GMT -
Rating 8
- Innovation 6
- Information 8
- Rumor -5
